These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 37539765)

  • 1. COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
    Hall VG; Teh BW
    J Infect Dis; 2023 Aug; 228(Suppl 1):S55-S69. PubMed ID: 37539765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
    Wu X; Wang L; Shen L; He L; Tang K
    J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
    Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
    Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.
    Khawaja F; Papanicolaou G; Dadwal S; Pergam SA; Wingard JR; Boghdadly ZE; Abidi MZ; Waghmare A; Shahid Z; Michaels L; Hill JA; Kamboj M; Boeckh M; Auletta JJ; Chemaly RF
    Transplant Cell Ther; 2023 Jan; 29(1):10-18. PubMed ID: 36273782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis.
    Abid MB; Rubin M; Szabo A; Longo W; Fenske TS; McCoy C; Lorge A; Abedin S; D'Souza A; Dhakal B; Shah NN; Hamadani M
    Transplant Cell Ther; 2024 Mar; 30(3):285-297. PubMed ID: 38142942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination for SARS-CoV-2 in Hematological Patients.
    Riccardi N; Falcone M; Yahav D
    Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
    Meir J; Abid MA; Abid MB
    Transplant Cell Ther; 2021 Dec; 27(12):973-987. PubMed ID: 34587552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.
    Guo W; Zheng Y; Feng S
    Front Cell Infect Microbiol; 2023; 13():1207225. PubMed ID: 37928188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of COVID-19 monoclonal antibodies on outcomes of COVID-19 infection in hematopoietic stem cell transplant and chimeric antigen receptor therapy recipients.
    Hahn EH; Li H; Sauter CS; Mossad SB
    Transpl Infect Dis; 2024 Aug; 26(4):e14322. PubMed ID: 38937864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.
    Haggenburg S; Hofsink Q; Rutten CE; Nijhof IS; Hazenberg MD; Goorhuis A
    Semin Hematol; 2022 Oct; 59(4):192-197. PubMed ID: 36805887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies.
    Ni B; Yanis A; Dee K; Chappell JD; Dulek DE; Kassim AA; Kitko CL; Thomas LD; Halasa N
    Blood Rev; 2022 Nov; 56():100984. PubMed ID: 35752546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
    Haggenburg S; Hofsink Q; Lissenberg-Witte BI; Broers AEC; van Doesum JA; van Binnendijk RS; den Hartog G; Bhoekhan MS; Haverkate NJE; Burger JA; Bouhuijs JH; Smits GP; Wouters D; van Leeuwen EMM; Bontkes HJ; Kootstra NA; Zweegman S; Kater AP; Heemskerk MHM; Groen K; van Meerten T; Mutsaers PGNJ; Beaumont T; van Gils MJ; Goorhuis A; Rutten CE; Hazenberg MD; Nijhof IS;
    JAMA Oncol; 2022 Oct; 8(10):1477-1483. PubMed ID: 35951338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
    Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
    Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of COVID-19 on cancer patients.
    Wekking D; Senevirathne TH; Pearce JL; Aiello M; Scartozzi M; Lambertini M; De Silva P; Solinas C
    Cytokine Growth Factor Rev; 2024 Feb; 75():110-118. PubMed ID: 38103990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
    Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
    Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy.
    Tamari R; Politikos I; Knorr DA; Vardhana SA; Young JC; Marcello LT; Doddi S; Devlin SM; Ramanathan LV; Pessin MS; Dunn E; Palazzo M; Bravo CD; Papanicolaou GA; Kamboj M; Perales MA; Chung DJ; Shah GL
    Blood Cancer Discov; 2021 Nov; 2(6):577-585. PubMed ID: 34778798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
    Rouphael N; Bausch-Jurken M
    J Infect Dis; 2023 Aug; 228(Suppl 1):S46-S54. PubMed ID: 37539761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments.
    Pfannes R; Pierzchalski A; Maddalon A; Simion A; Zouboulis CC; Behre G; Zenclussen AC; Westphal S; Fest S; Herberth G
    Front Immunol; 2023; 14():1087996. PubMed ID: 37187728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.